Nov 30, 2021 | by Kelly Prymicz, Commentary, Specialty Drug Management
If you’re a plan sponsor, you’re probably familiar with the drug Humira. That’s undoubtedly because it appears toward the top of your list of costliest drugs. Well, that might change soon. Or maybe not. It’s tough to tell. (more…)
Nov 29, 2021 | Commentary, Specialty Drug Management
What keeps you awake at night? For a couple years now, we’ve written about the number of mega-expensive new cell and gene therapies in the development pipeline. By “mega,” we generally mean therapies costing more than a million dollars. (more…)
